Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Kroeger N, et al. Among authors: wood la. Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15. Eur Urol. 2015. PMID: 25524810
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A, Eisenhauer E. Winquist E, et al. Invest New Drugs. 2006 Mar;24(2):159-67. doi: 10.1007/s10637-006-5938-1. Invest New Drugs. 2006. PMID: 16502349 Clinical Trial.
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.
MacKenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, Bjarnason G, Knox J. MacKenzie MJ, et al. Ann Oncol. 2011 Jan;22(1):145-148. doi: 10.1093/annonc/mdq320. Epub 2010 Jul 1. Ann Oncol. 2011. PMID: 20595449 Free article.
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.
Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F. Hotte SJ, et al. Among authors: wood l. Curr Oncol. 2011 Oct;18 Suppl 2(Suppl 2):S11-9. doi: 10.3747/co.v18is2.941. Curr Oncol. 2011. PMID: 21969807 Free PMC article.
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Harshman LC, et al. Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877847 Free PMC article.
244 results